EMEA-002172-PIP02-17

Key facts

Active substance
Monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation-stabilised F protein derived from the RSV A2 strain
Therapeutic area
  • Infectious diseases
  • Vaccines
Decision number
P/0318/2018
PIP number
EMEA-002172-PIP02-17
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen-Cilag International NV

E-mail: contact@janssen-emea.com
Tel.: +32 14602111

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating